Robert Allen, III Biography and Net Worth

Chief Scientific Officer of Invivyd

Robert Allen, Ph.D. has served as our Chief Scientific Officer since April 2023. He brings over 30 years of experience across the infectious disease space, most recently as the Chief Scientific Officer of SmartPharm Therapeutics, a subsidiary of Sorrento Therapeutics, from 2020 to 2023. During that time, he led efforts to develop gene-encoded monoclonal antibodies for COVID-19 that could be quickly adapted to respond to emerging variants of concern. He also served concurrently as Senior Vice President, Antiviral and Oncolytic Immunotherapy Development, at Sorrento Therapeutics. Prior to his time at SmartPharm Therapeutics, he held multiple senior scientific roles across the pharmaceutical and biotechnology industries including Sorrento Therapeutics, SIGA Technologies, and the Oregon Translational Research and Development Institute. Robert holds a Ph.D. in Microbiology from Columbia University, an M.S. in Applied Biology from Georgia Institute of Technology, and a B.S. in Biology from Rhodes College. He has published extensively in the field of virology and completed his postdoctoral training in virology at Washington University in St. Louis and Emory University.

What is Robert D. Allen, III's net worth?: The estimated net worth of Robert D. Allen, III is at least $197.49 thousand as of February 18th, 2026. Dr. Allen, III owns 114,487 shares of Invivyd stock worth more than $197,490 as of April 10th. This net worth estimate does not reflect any other assets that Dr. Allen, III may own. Learn More about Robert D. Allen, III's net worth.
How do I contact Robert D. Allen, III?: The corporate mailing address for Dr. Allen, III and other Invivyd executives is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. Invivyd can also be reached via phone at 781-819-0080 and via email at [email protected]. Learn More on Robert D. Allen, III's contact information.
Has Robert D. Allen, III been buying or selling shares of Invivyd?: Robert D. Allen, III has not been actively trading shares of Invivyd over the course of the past ninety days. Most recently, Robert D. Allen III sold 19,392 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a transaction totalling $30,639.36. Following the completion of the sale, the insider now directly owns 114,487 shares of the company's stock, valued at $180,889.46. Learn More on Robert D. Allen, III's trading history.
Who are Invivyd's active insiders?: Invivyd's insider roster includes Robert Allen, III (Chief Scientific Officer), and Julie Green (Chief Human Resources Officer). Learn More on Invivyd's active insiders.
Are insiders buying or selling shares of Invivyd?: In the last twelve months, Invivyd insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $125,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 504,826 shares worth more than $521,748.82. The most recent insider tranaction occured on February, 18th when insider Robert D Allen III sold 19,392 shares worth more than $30,639.36. Insiders at Invivyd own 25.4% of the company. Learn More about insider trades at Invivyd.
Information on this page was last updated on 2/18/2026.

Robert D. Allen, III Insider Trading History at Invivyd

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2026	Sell	19,392	$1.58	$30,639.36	114,487
2/17/2026	Sell	18,189	$1.54	$28,011.06	133,879
8/19/2025	Sell	27,420	$0.57	$15,629.40	53,068
8/18/2025	Sell	18,512	$0.65	$12,032.80	80,488

Robert D. Allen, III Buying and Selling Activity at Invivyd

Invivyd Company Overview

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $1.77

$1.62

$1.77

50 Day Range

MA: $1.59

$1.19

$1.90

2 Week Range

Now: $1.77

$0.46

$3.07

Volume

8,572,829 shs

Average Volume

3,074,031 shs

Market Capitalization

$499.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73